title: Prophylactic human papillomavirus vaccines: will they do their job?
abstract: The prophylactic HPV L1 virus like particle vaccines are highly efficacious preventing >98% of HPV 16/18 caused high grade cervical intra-epithelial neoplasia (CIN2/3) according to protocol group in phase III randomized clinical trials over approximately 4 years. Data from the trials together with postvaccine surveillance indicates that they have a good safety profile. As the current HPV vaccines include only two of the 15 oncogenic HPVs, they will not eliminate cervical cancer or the other HPV associated ano-genital diseases but could reduce, for example, the incidence of cervix cancer by up to 70-80%, if effectively delivered to adolescent females.
authors.affiliation: Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK. mas1001@cam.ac.uk
authors.forename: M
authors.initials: M
authors.lastname: Stanley
mesh_terms: D000293:Adolescent; D005260:Female; D014943:Global Health; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D016032:Randomized Controlled Trials as Topic; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control
chemical_list: D053918:Papillomavirus Vaccines